Magle Chemoswed Holding Gestion

Gestion contrôle des critères 2/4

Magle Chemoswed Holding's CEO is Justin Pierce, appointed in Jan 2015, has a tenure of 9.83 years. directly owns 0.94% of the company’s shares, worth €548.89K. The average tenure of the management team and the board of directors is 5.3 years and 8.8 years respectively.

Informations clés

Justin Pierce

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	9.8yrs
Propriété du PDG	0.9%
Durée moyenne d'occupation des postes de direction	5.3yrs
Durée moyenne du mandat des membres du conseil d'administration	8.8yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Justin Pierce (51 yo)

9.8yrs

Titularisation

Mr. Justin Pierce serves as Chief Executive Officer at Magle Chemoswed Holding AB (publ) since 2015.

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Hans Lidgard	Founder & Chairman	11.8yrs	SEK 248.00k	pas de données
Justin Pierce	Chief Executive Officer	9.8yrs	pas de données	0.94% € 548.9k
Petra Sjolin	Chief Financial Officer	4.8yrs	pas de données	pas de données
Fredrik Andersson	Chief Operations Officer	5.8yrs	pas de données	pas de données
Megi Medzmariashvili	Legal Counsel	5.8yrs	pas de données	pas de données
Helena Thedius	Chief Marketing & Innovation Officer	2.2yrs	pas de données	pas de données
Simon Jegou	Chief Strategy Officer	2.8yrs	pas de données	pas de données

5.3yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Gestion expérimentée: 52X's management team is seasoned and experienced (5.3 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Hans Lidgard	Founder & Chairman	11.8yrs	SEK 248.00k	pas de données
Sven-Christer Nilsson	Director	8.8yrs	SEK 138.00k	0.29% € 171.5k
Mats Pettersson	Director	8.8yrs	SEK 138.00k	1.17% € 686.1k
Claudia Lindwall	Staff Representative Director	3.8yrs	pas de données	pas de données
Malin Malmsjö	Director	8.8yrs	SEK 131.00k	pas de données
Ingela Fritzon	Staff Representative Director	5.8yrs	pas de données	pas de données
Martin Lidgard	Director	2.9yrs	SEK 131.00k	0.15% € 89.9k

8.8yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: 52X's board of directors are considered experienced (8.8 years average tenure).

Magle Chemoswed Holding Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

No independent directors

No independent directors

Magle Group Appoints New Chief Marketing and Innovation Officer

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

No independent directors

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Recent updates

Third quarter 2024 earnings released: EPS: kr0.89 (vs kr0.21 in 3Q 2023)

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 16%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) completed the acquisition of Amniotics AB (publ) (OM:AMNI).

Second quarter 2024 earnings released: EPS: kr0.015 (vs kr0.43 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.27 in 1Q 2023)

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Full year 2023 earnings released: EPS: kr1.13 (vs kr0.85 in FY 2022)

Magle Chemoswed Holding AB (publ) to Report Q4, 2024 Results on Feb 26, 2025

New minor risk - Financial data availability

No independent directors

Investor sentiment improves as stock rises 17%

Now 24% undervalued

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: kr0.87 (vs kr0.39 in FY 2021)

Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait

No independent directors

Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina

Magle Group Appoints New Chief Marketing and Innovation Officer

Investor sentiment improved over the past week

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

No independent directors

Full year 2021 earnings released: EPS: kr0.39 (vs kr0.24 in FY 2020)

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Full year 2020 earnings released: EPS kr0.24

Investor sentiment improved over the past week

Magle Chemoswed Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20 million.

New 90-day high: €3.60

New 90-day high: €3.28

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: €3.22

New 90-day high: €3.16

Magle Chemoswed Holding AB (Publ) Announces the Appointment of Joel Eklund as New Member of the Board

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen